Mid-term Business Plan 2027 Position we aspire to establish by 2033

Introduction

We aim to establish ourselves as a Global Specialized Player by 2033.

With a focus on the Psychiatry & Neurology and Oncology as priority disease areas, Sumitomo Pharma Group (the “Group”) will contribute to the betterment of healthcare and fuller lives of people worldwide through diverse approaches, including pharmaceutical products, regenerative medicine/cell therapy, and non-pharmaceutical solutions. In other areas, too, the Group will leverage its assets to deliver value to patients. With this, the Group aims to establish itself as a Global Specialized Player (“GSP”) by 2033.

The basic strategy of the Mid-term Business Plan 2027 (FY2023-FY2027), which was formulated in April 2023, is to make a “qualitative transformation” of the business structure and business practices.

In the meantime, the Company will build a foothold for achieving renewed growth after the expiration of the exclusive marketing period for LATUDA® (atypical antipsychotic) in the U.S. and for establishing a position as a GSP.

Approach to 2033

Established position as a Global Specialized Player (GSP)

Psychiatry & Neurology and Oncology as Priority Disease Areas, contribute to the betterment of healthcare
and fuller lives of people worldwide through diverse approaches (pharmaceutical products, regenerative
medicine/cell therapy, and non-pharmaceutical solutions), thus establishing a unique position globally.

    • Small molecule

      Small molecule

      Molecular
      design/synthesis
      based on accumulated
      experience/know-how

    • Regenerative
      medicine/cell therapy

      Regenerative medicine/cell therapy

      Know-how acquired by
      pioneering initiatives

    • Non-pharmaceutical
      (Frontier)

      Non-pharmaceutical(Frontier)

      To be developed
      in the
      mental
      resilience area

    • Other modalities

      Other modalities

      Pursuit of optimal
      modalities

    • Psychiatry & Neurology Area

      Diverse approaches to innovate the
      conventional treatment system

      • Our core area
      • Accumulated data, experience, and know-how
    • Oncology Area

      Distinguished products to innovate
      standard treatment

      • Carefully selected R&D pipeline
      • Unique fundamentals for drug discovery
    • Other Areas

      Deliver value to patients by
      leveraging our assets

      • Women’s health issues, urological diseases, diabetes
      • Rare diseases, infectious diseases